Daewoong Pharmaceutical said on Tuesday its antibiotic received an approval from the U.S. Food and Drug Administration.
The local pharmaceutical company is set to sell the generic drugs in the U.S. medical market for the first time as a Korean pharmaceutical company.
Daewoong's antibiotic is effective for pneumonia, peritonitis and bacterial meningitis. Unlike other antibiotic, it has fewer crossed tolerance and has higher external penetrability of virus. It has less side effects of nausea and vomit. Its volume is comprised of 500mg and 1g.
Based on the approval from the U.S. FDA, Daewoong plans to expand its business into the Middle East and the South America, which were hard to penetrate into in the past.
저작권자 © Korea IT Times 무단전재 및 재배포 금지
